Company: GANX
Filing Date: 2025-04-17
Form Type: PRE 14A
Source: 0001558370-25-004958
Chunk: 51

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-17
Form: PRE 14A
Chunk 51
---
 Goldstein, M.D.  |   |         55,558 |
| Hans Peter Hasler    |   |         55,558 |
| Eric Richman         |   |        370,824 |
| Gwen Melincoff       |   |         55,558 |
| Claude Nicaise, M.D. |   |         55,558 |
| Jeffrey Riley        |   |         81,982 |

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY On September 20, 2022, we adopted a formal non-executive director compensation policy based upon market research and advice from our compensation consultant. Under our non-employee director compensation policy, each of our non-employee directors is eligible to receive cash and equity compensation for service on our Board and committees of our Board.

Cash Compensation The non-employee director compensation policy provides our non-employee directors with the following cash compensation for their services:

| ​                                                                  | ​ |                        ​ |
| ​                                                                  |   | Annual Cash Retainer ($) |
| Annual retainer                                                    |   |                   40,000 |
| Additional retainer for non-executive chairperson                  |   |                   35,000 |
| Additional retainer for audit committee chair                      |   |                   17,000 |
| Additional retainer for audit committee member                     |   |                    7,500 |
| Additional retainer for compensation committee chair               |   |                   13,000 |
| Additional retainer for compensation committee member              |   |                    5,000 |
| Additional retainer for nominating and governance committee chair  |   |                   11,000 |
| Additional retainer for nominating and governance committee member |   |                    5,000 |

These retainers are payable in arrears in four equal quarterly installments within thirty days after the end of each calendar quarter, provided that the amount of such payment will be prorated for any portion of such quarter that the director is not serving on our Board. We also reimburse our directors for their reasonable out-of-pocket expenses in connection with attending our Board and Committee meetings. Equity Compensation In addition to cash compensation, each non-employee director is eligible to receive options under the 2022 Plan. Each option granted under the policy is a non-statutory stock option and has an exercise price per share equal to the fair market value of a share of common stock on the date of grant. Any options granted under this policy have a term of 10 years